BioSpace News Archive

Agreement with Biogen covers Samsung Bioepis’ biosimilar candidates in pre-clinical and clinical development, which reference two widely-used biologic medicines in ophthalmology: ranibizumab and aflibercept

MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the third quarter ended September 30, 2019 at 7:00 am Eastern Time on Thursday, November 14, 2019.

Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced the appointment of William Duke as Chief Financial Officer (CFO), effective November 25, 2019

Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it will host a key opinion leader (KOL) meeting on the health economics of norovirus disease on Thursday, November 14th in New York City.

BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced that the Company has appointed Gregg Russo as Senior Vice President, Human Resources, effectively immediately.

Presentation of 87 Abstracts Revealing New Insights into Acute Kidney Injury, Artificial Intelligence Technology, Home Dialysis, and Other Efforts to Improve Patient Outcomes

Study seeks to prove that Hoth’s and Zylo’s proprietary AEA-loaded Z-pods(TM) inhibits the development of CLE lesions in a standard animal model of lupus

Livestream Fundraiser to Feature Musical Performances, Celebrities & Influencers

Supports the first round of public private cooperative agreements to develop patient-centric quality measures in cancer for CMS

Biocept, Inc., a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial results for the three and nine months ended September 30, 2019 after the market closes on Wednesday, November 13, 2019.